XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
Status:
Withdrawn
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and efficacy of XERECEPT (human
Corticotropin-Releasing Factor, or hCRF) compared to dexamethasone in patients with primary
malignant glioma who require increased dexamethasone doses to control symptom of peritumoral
brain edema.